Recent approval of collagenase injections (Xiaflex) by FDA for treatment of Peyronie’s disease provides an exciting treatment option for men afflicted by Peyronie’s disease. Xiaflex does not seem to cure Peyronies completely but provides significant benefits in terms of curvature and symptoms.
Xiaflex is already covered by most insurance plans for treatment of Duputren’s contracture. This is encouraging since insurance companies are familiar with the medication. Now the challenge for for Xiaflex is to win coverage for Peyronie’s disease. Given recent FDA approval, we predict that coverage by major commercial insurances will follow.
We expect that commercial insurance companies including AETNA, Blue Cross, Unitedhealth, Wellpoint, Kaiser, Humana, Coventry, Highmark, Cigna, HealthNet, BCBS, HIP and others will process the FDA approval and institute broad-based coverage determinations within 6-8 months by September 2014.
At this point, coverage may be available by special request to insurance carriers. If you have significant symptoms from Peyronie’s disease, it is probably worth calling your insurance carrier to inquire if they will cover it.
It is not clear if Medicaid insurance will cover Peyronie’s. Our prediction that coverage for Xiaflex for Peyronie’s disease may be available in some states with generous Medicaid coverage such as New York, California, Connecticut, Washington DC, Rhode Island, New Jersey, Massachussets may cover Xiaflex for at least some men.
Blue Cross Plan coverage for Xiaflex for Peyronie’s
Xiaflex coverage by Medicare Coverage for Peyronie’s disease
United Healthcare Coverage for Xiaflex for Peyronie’s disease
Oxford coverage for Xiaflex for Peyronie’s disease